(Q44796764)

6 December 2017

title

VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy (English)

1 reference

6 December 2017

1 reference

Guishan Jin

1

1 reference

6 December 2017

Yiqiang Zhou

2

1 reference

6 December 2017

Qi Chai

3

1 reference

6 December 2017

Guidong Zhu

4

1 reference

6 December 2017

Fujian Xu

5

1 reference

6 December 2017

Fusheng Liu

6

1 reference

6 December 2017

publication date

22 November 2012

1 reference

Journal of Cancer Research and Clinical Oncology

6 December 2017

published in

1 reference

6 December 2017

volume

139

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

475-483

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-012-1347-3

6 December 2017

exact match

0 references

cites work

Stem and progenitor cell-mediated tumor selective gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Gene therapy of experimental brain tumors using neural progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Stem cells as therapeutic vehicles for the treatment of high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Intercellular trafficking and protein delivery by a herpesvirus structural protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Novel treatment strategies for malignant gliomas using neural stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Designer therapies for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Herpes simplex virus 1 VP22 regulates translocation of multiple viral and cellular proteins and promotes neurovirulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-beta in modulating proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Current progress in suicide gene therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1347-3

The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

21 January 2018

1 reference

12 December 2020

Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice.

1 reference

12 December 2020

Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines

1 reference

12 December 2020

Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach?

1 reference

12 December 2020

Intracellular trafficking of VP22 in bovine herpesvirus-1 infected cells

1 reference

12 December 2020

Primary brain tumours in adults

1 reference

12 December 2020

10.1007/S00432-012-1347-3

Identifiers

DOI

1 reference

6 December 2017

1 reference